Intervention Protocol

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary disease

  1. James B Geake1,*,
  2. Eli J Dabscheck2,
  3. Richard Wood-Baker3

Editorial Group: Cochrane Airways Group

Published Online: 17 OCT 2012

DOI: 10.1002/14651858.CD010139


How to Cite

Geake JB, Dabscheck EJ, Wood-Baker R. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary disease (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD010139. DOI: 10.1002/14651858.CD010139.

Author Information

  1. 1

    Monash Medical Centre, Thoracic and Sleep Medicine, Clayton, Victoria, Australia

  2. 2

    Alfred Hospital, Allergy Immunology and Respiratory Medicine, Prahan, Victoria, Australia

  3. 3

    University of Tasmania, Menzies Research Institute Tasmania, Hobart, Tasmania, Australia

*James B Geake, Thoracic and Sleep Medicine, Monash Medical Centre, Clayton, Victoria, 3168, Australia. james.geake@southernhealth.org.au. bod182au@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 17 OCT 2012

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kayleigh M Kew, Chris Mavergames, Julia AE Walters, Long-acting beta2-agonists for chronic obstructive pulmonary disease, The Cochrane Library,
  2. 2
    Kayleigh M Kew, Sofia Dias, Christopher J Cates, Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis, The Cochrane Library,